Deals
Teva Adds MicroDose to Respiratory Business in $165 Million Deal
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., which said six months ago it would focus on treatments for respiratory and central nervous system illnesses, announced it will acquire U.S.-based inhaler developer MicroDose Therapeutx.
Teva will pay $40 million for MicroDose’s outstanding shares and as much as $125 million in additional payments pending regulatory and development milestones, plus royalties, the Petach Tikva, Israel-based company said in a statement today. MicroDose is developing MDT-637 for respiratory syncytial virus, a respiratory virus that infects the lungs and breathing passages.